engraftment High-dose chemotherapy (HDC) followed by autologous stem cell transplant (ASCT) is used commonly for a variety of hematologic malignancies. The preparative regimens are designed to be myeloablative, resulting in severe myelosuppression and associated sequelae such as febrile neutropenia, thrombocytopenia and anemia. The transplant-related mortality is usually in the range of 5-10%. 1 Most of these events are due to infectious complications during the time preceding engraftment. Myeloid growth factors (viz filgrastim and sargramostim) have been used in the post transplant period to accelerate neutrophil engraftment. The results have been variable, and were dependent on the source of the stem cells.
Filgrastim (r-met Hu-G-CSF) is a recombinant growth factor that is approved for prevention of chemotherapyinduced neutropenia after standard dose chemotherapy. ASCO (American Society of Clinical Oncology) guidelines recommend use of colony-stimulating factors after ASCT. Filgrastim, after HDC and autologous bone marrow transplant, has been shown to accelerate neutrophil engraftment as compared to no growth factors, and to decrease the number of days of febrile neutropenia. 2 No disadvantage was observed when delaying the start of filgrastim until day þ 7 after transplant as compared to starting on day þ 1. 3 Pegylation of filgrastim leads to prolongation of half-life without loss of in vivo activity. [4] [5] [6] Pegfilgrastim (Neulasta s ; Amgen Inc., Thousand Oaks, CA, USA) has been approved by the Food and Drug Administration for prevention of chemotherapy-induced neutropenia after standard dose chemotherapy. However, the safety and efficacy of pegfilgrastim for neutrophil support following chemotherapy to patients undergoing HDC and ASCT is not known. We undertook a prospective, single institute study to evaluate the efficacy of pegfilgrastim after autologous transplant.
Patients and methods
In all, 38 patients, who were eligible for HDC and autologous peripheral blood stem cell transplant, were enrolled from August 2003 until March 2004. Patients were eligible for transplant if they fulfilled standard institutional criteria and had no prior history of allergy to filgrastim or pegfilgrastim. Only patients with diagnoses of multiple myeloma or lymphoma and undergoing first autologous transplant were eligible. All patients signed an IRB (Institution Review Board)-approved informed consent.
Stem cell mobilization and collection
All patients had an adequate number of peripheral blood stem cells (42 Â 10 6 CD34 þ cells/kg of recipient adjusted ideal body weight). All patients underwent peripheral stem cell collection in a uniform manner with chemotherapy (cyclophosphamide, 3000 mg/m 2 ) followed by daily filgrastim (10 mg/kg/day) until peripheral blood absolute CD34 count was higher than 0.15 ( Â 10 9 /l). Peripheral blood stem cells were then collected using leukapheresis. Pheresis was repeated on the second day if an inadequate number of CD34 þ cells were collected with the first pheresis.
Conditioning regimens
The day of stem cell reinfusion was termed day 0. Patients with multiple myeloma were conditioned with high-dose melphalan at a dose of 100 mg/m 2 intravenously over 30 min on day À3, and day À2. For patients with lymphoma, the conditioning regimen consisted of highdose cyclophosphamide, etoposide and BCNU. Cyclophosphamide 1800 mg/m 2 was given intravenously over 2 h on days À6, À5, À4 and À3. Bladder irrigation was used for prophylaxis against hemorrhagic cystitis. Etoposide was dosed at 3600 mg/m 2 as a continuous infusion over 36 h starting day À7. BCNU was given at 400 mg/m 2 on day À2. The BCNU dose was reduced to 300 mg/m 2 for patients who had received previous thoracic radiation.
Pegfilgrastim
All patients received a single injection of pegfilgrastim dosed at 6 mg subcutaneously, approximately 24 h after the conclusion of the stem cell infusion.
Engraftment
Neutrophil engraftment was defined as first of 3 consecutive days of an ANC equal or greater than 0.5 Â 10 9 /l after a previous nadir. Platelet engraftment was defined as platelet count of equal or greater than 20 Â 10 9 /l, without a platelet transfusion in the preceding 7 days. 7 The above data were collected prospectively on a daily basis until the end of the study, which was defined as follows: engraftment of neutrophils and platelets, absence of any fever, no requirement for intravenous antibiotic and total parenteral nutrition.
Infection prophylaxis and treatment
All patients were started on prophylactic quinolone, flucanozole and valacyclovir on day À1. Febrile neutropenia was defined as fever 438.01C and an absolute neutrophil count (ANC) o1 Â 10 9 /l. Patients with febrile neutropenia were treated empirically with broad-spectrum antibiotics per standard institutional protocol. Data were prospectively collected regarding days of antibiotic and antifungal use. Antibiotic use was classified as prophylactic, empiric or for documented infections.
Transfusions
Patients received platelet transfusions (4 U) for platelet count less than 20 Â 10 9 /l if the setting of an ANC was less than 0.5 Â 10 9 /l, and for platelet count less than 10 Â 10 9 /l if the ANC was equal or more than 0.5 Â 10 9 /l. Packed red blood cells were transfused (2 U if packed cell volume was less than 25%).
Nutrition
Patients were followed by the nutrition team daily and were started on total parenteral nutrition if oral caloric intake was less than 50% of expected intake. Parenteral nutrition was discontinued once patients were able to take greater than 50% of expected calories orally.
Statistics
The primary end points were safety and efficacy of pegfilgrastim after HDC and ASCT. Efficacy was measured by time to neutrophil engraftment and comparisons were made with historical group of patients who received no growth factors or prophylactic filgrastim after HDC and ASCT. The incidence of febrile neutropenia, antibiotic use, transfusion requirements and use of total parenteral nutrition were secondary end points. Descriptive statistics, including means, standard deviations and ranges for continuous parameters, as well as percentages and frequencies for categorical parameters, were calculated. Groups with nominal outcome were compared using w 2 test. Groups with continuous variable outcomes were compared using Wilcoxon's rank-sum test, when data distribution was not normal. Continuous variables were compared across cohorts using Kruskal-Wallis test or Mann-Whitney U-test, depending on number of cohorts.
In order to do sample size calculations, mean time to engraftment without any growth factor support was analyzed from the transplant database. This was 13.5 days with standard deviation of 3.7 days. The mean time to engraftment for historical group (received prophylactic filgrastim after HDC and ASCT) was 10.9 days with a standard deviation of 1.8 days. Calculations for sample size estimation were based on the observation that the effect of pegfilgrastim on neutrophil recovery after standard dose chemotherapy is equivalent to standard dose filgrastim.
The sample size estimation was completed using the Student t-test. With a sample size of 76 (38 patients for treatment arm and 38 patients for historical control), it provides at least 90% power to detect a difference of 3 days of time to engraftment between two treatment groups (pegfilgrastim vs group receiving no growth factors), with two-sided type I error ¼ 5%. SPSS version 12.0 for Windows was used for statistical analysis.
Historical control
Patients with multiple myeloma or lymphoma undergoing their first HDC and ASCT after January 2001 were selected from the transplant database as historical controls. Patients were included in the cohort only if they underwent cyclophosphamide plus filgrastim mobilization, had a minimum stem cell dose of 2 Â 10 6 CD34 þ cells/kg and had preparative regimens identical to those used in this study. From this cohort, 38 sequential patients who received prophylactic filgrastim until neutrophil engraftment and 38 patients who received no growth factors after HDC and ASCT were selected. All patients in the historical group were similar to the study cohort regarding method of stem cell mobilization, stem cell dose and type of conditioning regimen for the specific disease (Table 1) . Time to neutrophil and platelet engraftment data was available for all patients. The definition of engraftment was identical as used in the current study. Secondary end point data, including use of antimicrobial prophylaxis and treatment, were not available on historical controls and were not compared.
Results
In all, 38 patients were enrolled at a single center from September 2003 until March 2004. One patient died on day 0 due to cardiac toxicity from HDC and never received stem cell infusion. Patient characteristics pertaining to demographics, disease characteristics and stem cell dose of 37 patients are as shown in Table 1 .
Infection outcome
Febrile neutropenia was seen in 49% (18/37) of patients. The median duration of febrile neutropenia was 2.5 days (range, 1-6 days). There was no difference in the incidence of febrile neutropenia in patients with myeloma compared to lymphoma (50 vs 60%, P ¼ 0.59). Only 12% (14/121) of blood cultures were positive. The predominant organism was coagulase-negative staphylococcus (13/14 blood cultures). The incidence of patients requiring intravenous antibiotics was 64% (23/36) with a median duration of 8 days (range, 2-24 days). Intravenous antibiotics were empirically used in 46% (17/37) of patients for a median duration of 6 days (range, 1-18 days). For treatment of documented infections, intravenous antibiotics were used in 39% of patients for a median duration of 7.7 days (range, 4-14 days).
Toxicity
There were no deaths on this study. No toxicity could be specifically attributed to pegylated filgrastim injection in the setting of HDC and ASCT. No patients developed engraftment syndrome.
Transfusions
All patients required platelet transfusion. All except two patients required packed red blood cell transfusion. The median number of platelet and packed red blood cell transfusions were 8 U (range, 4-28 U) and 4 U (range, 1-18 U). 
Nutrition
The incidence of patients requiring total parenteral nutrition was 46% (17/37) with a median duration of 7 days (range, 3-36 days).
Engraftment
The mean stem cell dose was higher in patients with myeloma (7.29 Â 10 6 CD34 þ cells/kg, 95% CI 5.81-8.77) compared to patients with lymphoma (4.72 Â 10 6 CD34 þ cells/kg, 95% CI 2.06-7.37) (P ¼ 0.012). The median time to platelet engraftment was 18 days (range, 10-28 days). The mean ANC on day 0 for patients with myeloma was significantly higher than in patients with lymphoma (3.28 vs 0, Po0.001). The median time to neutrophil engraftment was 10 days (range, 8-13 days). The time to neutrophil engraftment in patients with myeloma or lymphoma was not different (10.1 vs 9.6 days, P ¼ 0.156). Patients with myeloma, however, had fewer days of ANC o0.5 Â 10 9 /l compared to patients with lymphoma (6.4 vs 9.9 days, Po0.001). This did not translate into a lower incidence of febrile neutropenia in patients with myeloma. The engraftment kinetics of patients with myeloma and lymphoma are shown in Figure 1 .
Neutrophil and platelet engraftment in this patient cohort were compared with a cohort of 38 patients (similar diagnoses, method of stem cell collection, conditioning regimen and stem cell dose) at our institute, who received filgrastim at 5 mg/kg subcutaneously daily, starting at day þ 1 or day þ 4 until ANC 40.5 Â 10 9 /l for 3 consecutive days. In these patients, the mean time to neutrophil engraftment and platelet engraftment were 10.9 days (range, 8-17 days) and 18.7 days (range, 17-20 days). There was no clinically significant difference in the median time to neutrophil engraftment between study group and the cohort that received filgrastim prophylaxis (10 vs 10.5 days). The mean time to platelet engraftment between the study group and the filgrastim group was not different (17.8 vs 18.7 days, P ¼ 0.53).
Neutrophil engraftment in the study group (10 days, 95% CI 9.64-10.3) was significantly shorter than in the historical group receiving no filgrastim (13.7 days, 95% CI 12.7-15) after HDC and SCT (Po0.001). There was no difference in platelet engraftment in the study group (17.8 days, 95% CI 16.5-19) compared with the group receiving no filgrastim (18.1 days, 95% CI 16.0-20.2).
Discussion
Our study shows that pegfilgrastim can be used safely after HDC and ASCT. Time to neutrophil engraftment is significantly shorter when compared with a historical group that received no filgrastim, and similar to the group that received filgrastim prophylaxis after HDC and ASCT.
Pegfilgrastim (Amgen Inc., Thousand Oaks, CA, USA) has been studied in animal and normal human volunteers and its safety and efficacy has been confirmed. The median plasma half-life values for pegfilgrastim range from 15 to 80 h and are independent of dose. Using nephrectomized rat models, it has been shown that renal clearance is not important. In initial studies, pegfilgrastim was dosed on body weight. It was shown in phase II and subsequently in randomized, double-blind studies that 100 mg/kg of pegylated filgrastim was equivalent to daily filgrastim at 5 mg/kg. 8, 9 Retrospective analysis of these studies showed that patients receiving 5-7 mg of pegylated filgrastim had results equivalent to 5 mg/kg/day of filgrastim. A randomized, double-blind, placebo-controlled study compared single fixed 6 mg dose of pegfilgrastim to daily filgrastim at 5 mg/kg/day (upto 14 days) after standard dose chemotherapy, and has shown that pegfilgrastim is equivalent to daily filgrastim in decreasing duration of significant neutropenia. 10 The efficacy and dosing of pegfilgrastim after HDC and ASCT has not been established. In this study, we enrolled patients undergoing HDC and ASCT and used pegfilgrastim 6 mg subcutaneously on day þ 1. There were no adverse side effects related specifically to pegfilgrastim. The median time to neutrophil engraftment was 10 days. The engraftment data were compared with data from a historical patient group who received daily filgrastim starting either at day þ 1 or þ 4 after HDC and ASCT. The characteristics of this group regarding disease type, preparative regimens, method of stem cell collection and stem cell dose are compared with the study group in Table 1 .
Patients with multiple myeloma in the historical cohort received more stem cells compared to the study group. This reflects the changing practice of tandem autologous transplants for myeloma patients. There was no difference in time to neutrophil engraftment between the two groups. This study shows conclusively that 6 mg of pegfilgrastim administered subcutaneously on day þ 1 after HDC and ASCT leads to a significant shorter time to neutrophil engraftment compared to a historic cohort of patients who received no growth factors after HDC and ASCT. The mean ANC on day 0 was higher in patients with myeloma when compared with patients with lymphoma. This reflects the more prolonged preparative regimen in patients with lymphoma. Patients with myeloma had fewer days of severe neutropenia as compared to patients with lymphoma. The engraftment kinetics in these two groups of patients is markedly different as outlined in Figure 1 . This, however, did not lead to any significant difference in time to neutrophil engraftment or incidence of febrile neutropenia among the two groups. Some investigators have reported a detrimental effect on platelet engraftment with use of granulocyte colony-stimulating factors after HDC and ASCT. 11 This was not evident in our study as the time to platelet engraftment was similar in the study group when compared with the historical groups that received either no filgrastim or prophylactic filgrastim after HDC and SCT.
This study shows that pegfilgrastim can be used safely and effectively to decrease time to neutrophil engraftment after HDC and ASCT. The time to neutrophil engraftment is comparable to that seen with daily filgrastim. The convenience of one injection on day þ 1 makes it attractive for use in outpatient transplant setting. Cost-effective data analysis would be important to recommend general use of pegfilgrastim after HDC and ASCT.
